Like other medicine with mu-opioid agonist activity, NUCYNTA® is contraindicated in people with sizeable respiratory despair in unmonitored options or the absence of resuscitative equipment. 1st marketed in Europe in 2011, tapentadol is remaining promoted being a mixed mechanism of action analgesic that is productive throughout a broad spectrum of https://billy050gkr3.worldblogged.com/profile